Identification of Glyceraldehyde‐3‐Phosphate and Alcohol Dehydrogenases as Autoantigens in Doberman Hepatitis

Dyggve, H.; Jarva, Hanna; Spillmann, Thomas; Speeti, M.; Meri, Seppo

doi:10.1111/sji.12575

Cited by 4 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specific criteria for the diagnosis of immune‐mediated hepatitis in dogs have not been developed. An immune basis in some dogs with idiopathic CH is suggested by several criteria (Table ) which include the presence of lymphocytic infiltrates in the liver, abnormal expression of major histocompatibility complex class II proteins, positive serum autoantibodies, familial history of liver disease, association with other immune‐mediated disorders, female predisposition, and favorable response to immunosuppression . A presumptive clinical diagnosis of immune‐mediated CH in the dog requires elimination of other etiologies and a favorable response to immunosuppressive treatment.…”

Section: Etiologymentioning

confidence: 99%

“…Details and evidence for breed, sex, and age predispositions are summarized in Supporting Information Table S1. There is strong evidence in ≥2 studies for an increased prevalence of CH in BT, Doberman Pinschers, LR, Dalmatians, American and English Cocker Spaniels, English Springer Spaniels, and West Highland White Terriers in several countries. In addition, in Sweden the Scottish Terrier, and in the United Kingdom the Cairn Terrier, Great Dane, Samoyed, Yorkshire Terrier, and Jack Russell Terrier are predisposed .…”

Section: Signalment and Clinical Signsmentioning

confidence: 99%

“…An immune basis in some dogs with idiopathic CH is suggested by several criteria (Table 5) which include the presence of lymphocytic infiltrates in the liver, abnormal expression of major histocompatibility complex class II proteins, positive serum autoantibodies, familial history of liver disease, association with other immune-mediated disorders, female predisposition, and favorable response to immunosuppression. 1,7,9,14,15,20,32,34,[146][147][148][149][150][151][152][153][154][155][156][157][158][159][160][161][162][163]165,167,168 A presumptive clinical diagnosis of immune-mediated CH in the dog requires elimination of other etiologies and a favorable response to immunosuppressive treatment. Currently, the lack of commercially available tests to detect liver-specific antibody-antigen interactions or cell immunosensitization in dogs with CH limits the definitive determination of an immune-mediated etiology.…”

Section: Immune-mediated Chmentioning

confidence: 99%

“…Details and evidence for breed, sex, and age predispositions are summarized in Supporting Information Table S1. There is strong evidence in ≥2 studies for an increased prevalence of CH in BT, 24,35 Doberman Pinschers, 7,20,[43][44][45]150,[153][154][155][156]158,162,[169][170][171][172][173] LR, 8,10,14,21,27,138,158,162,163,168,169,172 Dalmatians, [39][40][41]157,158,169,174 American and English Cocker Spaniels, 27,48,156,157,162,163,165,169,175 English Springer Spaniels, 158,…”

Section: Signalmentmentioning

confidence: 99%

See 3 more Smart Citations

ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs

Webster

Cullen

Penninck

et al. 2019

Veterinary Internal Medicne

198

View full text Add to dashboard Cite

This consensus statement on chronic hepatitis (CH) in dogs is based on the expert opinion of 7 specialists with extensive experience in diagnosing, treating, and conducting clinical research in hepatology in dogs. It was generated from expert opinion and information gathered from searching of PubMed for manuscripts on CH, the Veterinary Information Network for abstracts and conference proceeding from annual meetings of the American College of Veterinary Medicine and the European College of Veterinary Medicine, and selected manuscripts from the human literature on CH. The panel recognizes that the diagnosis and treatment of CH in the dog is a complex process that requires integration of clinical presentation with clinical pathology, diagnostic imaging, and hepatic biopsy. Essential to this process is an index of suspicion for CH, knowledge of how to best collect tissue samples, access to a pathologist with experience in assessing hepatic histopathology, knowledge of reasonable medical interventions, and a strategy for monitoring treatment response and complications.

show abstract

Section: Etiologymentioning

confidence: 99%

Section: Signalment and Clinical Signsmentioning

confidence: 99%

Section: Immune-mediated Chmentioning

confidence: 99%

“…Details and evidence for breed, sex, and age predispositions are summarized in Supporting Information Table S1. There is strong evidence in ≥2 studies for an increased prevalence of CH in BT, 24,35 Doberman Pinschers, 7,20,[43][44][45]150,[153][154][155][156]158,162,[169][170][171][172][173] LR, 8,10,14,21,27,138,158,162,163,168,169,172 Dalmatians, [39][40][41]157,158,169,174 American and English Cocker Spaniels, 27,48,156,157,162,163,165,169,175 English Springer Spaniels, 158,…”

Section: Signalmentmentioning

confidence: 99%

See 2 more Smart Citations

ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs

Webster

Cullen

Penninck

et al. 2019

Veterinary Internal Medicne

198

View full text Add to dashboard Cite

show abstract

“…No common autoantibody was detected. An ELISA was used in each of these papers, either alone 92 or in combination with other techniques 93,94 . All but 1 of these studies were small, and 1 was midsized 93 .…”

Section: Resultsmentioning

confidence: 99%

A scoping review of autoantibodies as biomarkers for canine autoimmune disease

Treeful

Coffey

Friedenberg

2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Autoantibody biomarkers are valuable tools used to diagnose and manage autoimmune diseases in dogs. However, prior publications have raised concerns over a lack of standardization and sufficient validation for the use of biomarkers in veterinary medicine. Objectives Systematically compile primary research on autoantibody biomarkers for autoimmune disease in dogs, summarize their methodological features, and evaluate their quality; synthesize data supporting their use into a resource for veterinarians and researchers. Animals Not used. Methods Five indices were searched to identify studies for evaluation: PubMed, CAB Abstracts, Web of Science, Agricola, and SCOPUS. Two independent reviewers (AET and ELC) screened titles and abstracts for exclusion criteria followed by full‐text review of remaining articles. Relevant studies were classified based on study objectives (biomarker, epitope, technique). Data on study characteristics and outcomes were synthesized in independent data tables for each classification. Results Ninety‐two studies qualified for final analysis (n = 49 biomarker, n = 9 epitope, and n = 34 technique studies). A high degree of heterogeneity in study characteristics and outcomes reporting was observed. Opportunities to strengthen future studies could include: (1) routine use of negative controls, (2) power analyses to inform sample sizes, (3) statistical analyses when appropriate, and (4) multiple detection techniques to confirm results. Conclusions These findings provide a resource that will allow veterinary clinicians to efficiently evaluate the evidence supporting the use of autoantibody biomarkers, along with the varied methodological approaches used in their development.

show abstract

Copper hepatopathies in Australian dogs

Mutton,

Yeomans,

White

2024

Aust Veterinary J

View full text Add to dashboard Cite

IntroductionTo evaluate hepatopathies in Australian dogs according to the World Small Animal Veterinary Association (WSAVA) guidelines. Specifically, to describe the prevalence and survival of dogs with copper‐associated hepatopathy.Materials and methodsMedical records from the Small Animal Specialist Hospital were reviewed to identify dogs with liver disease and liver biopsy between November 2008 and November 2021. Liver histopathology reports were reviewed with a board‐certified veterinary pathologist and classified according to the WSAVA guidelines. Histopathology reports and clinical records were reviewed to ascertain the most important histological process for statistical analysis. Copper‐associated hepatopathy was defined as (i) histological evidence of copper accumulation in centrilobular areas (Zone 3) associated with hepatocyte necrosis, inflammation with copper‐laden macrophages and chronic hepatitis (ii) histochemical copper staining showing hepatocyte copper accumulation in the centrilobular areas and iii) hepatic copper measurement with concentrations greater than 600 μg/g dry weight of liver. Dogs with primary inflammatory parenchymal disease included dogs with copper‐associated hepatopathy, idiopathic chronic hepatitis, non‐specific reactive hepatitis, chronic bacterial hepatitis and immune‐mediated chronic hepatitis. Descriptive statistics were performed for all dogs. Age, weight and clinicopathologic data were compared between dogs with copper‐associated hepatopathy and dogs with other causes of chronic primary inflammatory parenchymal liver disease (Kruskal–Wallis test). Survival times were calculated and compared (Kaplan–Meier curves and log rank test) between dogs with copper‐associated hepatopathy and dogs with other chronic primary inflammatory parenchymal liver diseases. Breed was evaluated to determine the breed most commonly affected with copper‐associated hepatopathy and identify any breed in which this disease has not previously been described.ResultsSixty‐seven (43 female, 24 male) dogs with a median age of 7.8 years (quartile [Q] Q1‐Q3 4.5–9.6 years) were included. Thirteen dogs had copper‐associated hepatopathy, eight dogs had idiopathic chronic hepatitis, eight dogs had non‐specific reactive hepatitis, seven dogs had disorders associated with portal hypertension, five dogs had chronic bacterial hepatitis and four dogs had immune‐mediated chronic hepatitis. Compared with dogs with other causes of chronic primary inflammatory parenchymal liver disease, dogs with copper‐associated hepatopathy tended to be younger (6.73 vs. 8.01 years, P = 0.057) and heavier (19.8 vs. 9.6 kg, P = 0.052) than dogs with other causes of primary chronic inflammatory parenchymal diseases. There was no statistically significant difference when ALT (P = 0.30), ALP (P = 0.18) and total bilirubin (P = 0.13) were compared between the two groups.The median survival time for all dogs after liver biopsy was 2010 days (CI 1321 days – not reached). There was no significant difference in survival between dogs with copper‐associated hepatopathy and dogs with other causes of chronic primary inflammatory parenchymal liver disease (P = 0.5).ConclusionsCopper‐associated hepatopathy was common among Australian dogs with chronic hepatopathies, occurring in younger and heavier dogs than other causes of primary inflammatory parenchymal liver disease. Clinical pathology is not useful for differentiating between copper‐associated hepatopathy and other causes of chronic primary inflammatory parenchymal liver disease. When copper‐associated hepatopathy is treated, the prognosis can be good. This is the first report of copper‐associated hepatopathy in Australian Cavalier King Charles Spaniels.

show abstract

Identification of Glyceraldehyde‐3‐Phosphate and Alcohol Dehydrogenases as Autoantigens in Doberman Hepatitis

Cited by 4 publications

References 29 publications

ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs

ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs

A scoping review of autoantibodies as biomarkers for canine autoimmune disease

Copper hepatopathies in Australian dogs

Contact Info

Product

Resources

About